SCHEMBL902339

SCHEMBL902339

Cc1ccc(Cc2c(C)nc3c(C(=O)N4CCCC4)cnn3c2O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.67
HSD17B10 Q99714 8/20 0.67
TSHR P16473 6/20 0.67
RUVBL1 Q9Y265 4/20 0.63
HPGD P15428 11/20 0.60
KDM4E B2RXH2 10/20 0.60
RUVBL2 Q9Y230 1/20 0.59
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
LMNA P02545 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
NPC1 O15118 1/20 0.56
GLA P06280 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902537 0.92 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL902549 0.91 ALDH1A1 (0.71) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL15274740 0.91 ALDH1A1 (0.71) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL15262379 0.85 HSD17B10 (0.80) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL902831 0.85 ALDH1A1 (0.83) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL902315 0.83 KDM4E (0.84) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL902518 0.82 KDM4E (0.65) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL902610 0.81 KDM4E (0.84) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL15277552 0.81 ALDH1A1 (0.66) ALDH1A1HSD17B10TSHRRUVBL1HPGD
SCHEMBL15262398 0.81 HSD17B10 (0.61) ALDH1A1HSD17B10TSHRRUVBL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US claimed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP claimed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO claimed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 ALDH1A1 441/4885HSD17B10 2138/4885TSHR 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.